Search results

1598 results

Sorted by Relevance . Sort by Date

  1. Postnatal care

    In development [GID-NG10070] Expected publication date: 07 April 2021

  2. Acute coronary syndromes

    In development [GID-NG10085] Expected publication date: 18 November 2020

  3. Shared decision making

    In development [GID-NG10120] Expected publication date: 17 June 2021

  4. Antenatal care

    In development [GID-NG10096] Expected publication date: 11 August 2021

  5. Acne Vulgaris: Management

    In development [GID-NG10109] Expected publication date: 09 June 2021

  6. Caesarean section (update)

    In development [GID-NG10081] Expected publication date: 31 March 2021

  7. Inducing labour (update)

    In development [GID-NG10082] Expected publication date: 14 October 2021

  8. Diabetes update

    In development [GID-NG10152] Expected publication date: TBC

  9. Pernicious anaemia

    In development [GID-NG10176] Expected publication date: 23 March 2023

  10. Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma (TA478)

    Evidence-based recommendations on brentuximab vedotin (Adcetris) for treating relapsed or refractory systemic anaplastic large cell lymphoma in adults

  11. Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the knee (TA477)

    Evidence-based recommendations on autologous chondrocyte implantation (ACI) in people with symptomatic articular cartilage defects of the knee

  12. Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer (TA476)

    Evidence-based recommendations on paclitaxel as albumin-bound nanoparticles (nab-paclitaxel; Abraxane) for untreated metastatic pancreatic cancer in adults

  13. Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck (TA473)

    Evidence-based recommendations on cetuximab (Erbitux) for treating recurrent or metastatic squamous cell cancer of the head and neck in adults

  14. Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer (TA495)

    Evidence-based recommendations on palbociclib (Ibrance) as initial endocrine-based therapy for hormone receptor-positive, HER2-negative, locally advanced or

  15. Ibrutinib for treating Waldenstrom's macroglobulinaemia (TA491)

    Evidence-based recommendations on ibrutinib (Imbruvica) for treating Waldenstrom's macroglobulinaemia (non-Hodgkin lymphoma) in adults after at least 1 therapy